Silexion Therapeutics Announces Exercise of Warrants for $3.3 Million Gross Proceeds

Core Viewpoint - Silexion Therapeutics Corp. has entered into agreements for the immediate exercise of warrants to purchase 2,221,523 ordinary shares at an exercise price of $1.35 per share, expecting gross proceeds of approximately$3.3 million, which will be used for working capital and general corporate purposes [1][3]. Group 1: Financial Details - The gross proceeds from the exercise of the warrants are expected to be approximately $3.3 million before deducting fees and expenses [1]. - The company will issue new unregistered warrants to purchase the same number of ordinary shares at an exercise price of$1.50 per share, with a term of twenty-four months [3]. - The additional payment for the new warrants totals $277,690.38, included in the gross proceeds [3]. Group 2: Regulatory and Compliance - The new warrants and the shares issuable upon their exercise are not registered under the Securities Act of 1933 and may not be sold in the U.S. without registration or an exemption [4]. - The company has agreed to file a registration statement with the SEC for the resale of the ordinary shares from the new warrants [4]. Group 3: Company Overview - Silexion Therapeutics is focused on developing RNA interference therapies for KRAS-driven cancers, with its first-generation product, LODER™, showing promise in Phase 2 trials for non-resectable pancreatic cancer [6]. - The company is advancing its next-generation siRNA candidate, SIL-204, which targets a broader range of KRAS mutations and has shown significant potential in preclinical studies [6].